First AD

Second AD

Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

Video content above is prompted by the following:

Briefly comment on key findings and final OS data from the 

 trial, evaluating niraparib 1L maintenance therapy in newly diagnosed advanced ovarian cancer. 

What implications do these findings have and what impact may they have on the treatment paradigm for ovarian cancer?

What new insights can be drawn about long-term responders to maintenance niraparib from the recent subanalysis of the 

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Advancements in the Management of Gynecological Cancers: ESMO 2024 

Peer Exchange

Panelists discuss optimal durations for PARP inhibitor maintenance therapy in ovarian cancer, exploring how long patients are typically kept on PARPi in both first-line and second-line maintenance settings.